tru4-1

Remdesivir and Molnupiravir belong to what class of therapeutic agents?

The SARS-CoV-2 viral particle is non-enveloped.

What are the advantages associated with the use of nanomaterials in the diagnosis and treatment of SARS-CoV-2 infection?

Why are most of the novel specific therapies limited to hospitalised patients?

Pathogenetic treatments of SARS-CoV-2 infection target: